”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

Introducing Amferia wound dressing for animal care — binds and kills bacteria without harming the body

How antimicrobial hydrogel can revolutionize clinical treatments

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

How it works:

For decades, we’ve known that antimicrobial peptides are potent killers of bacteria. Peptides carry a positive electrostatic charge, which naturally attracts the negative charge bacteria carry. Once attached, the knife-like structure of peptides puncture bacterial membranes, killing the cells.  

What hasn’t been known—until now—is how to protect vulnerable parts of the peptide from natural enzymes in the human body. In nature, peptides are fragile molecules. Enzymes can destroy them in seconds. To be effective bacteria killers, peptides need protection.  

To be effective bacteria killers, peptides need protection.  

Amferia solves that problem with an innovative, patented hydrogel platform that encases peptides in a solid gel, leaving only the knife-like structure free to attract and puncture bacterial cells.

Because peptides kill bacteria in a physical—as opposed to chemical—process, Amferia products kill even bacteria that has become resistant to antibiotic drugs.

Amferia’s hydrogel stabilizes and protects the peptides for up to five days in biological environments, keeping them actively killing bacteria that entire time. Amferia harnesses peptides in a safe, stable, non-toxic and clinically applicable form, allowing them to kill bacteria without harming anything else in the body.

Amferia’s proprietary antimicrobial technology consists of bioinspired and amphiphilic antibacterial polymers that target, rapidly bind and kill upto 99.99% of the bacteria upon contact, including numerous strains of antibiotic resistant bacteria like MRSA and MDR E. Coli

The material is selective and targets only bacteria while being entirely non-toxic to human and animal body. 

Now, Amferia has developed this platform into its first in-market product —wound dressing for animal care. Ultimately, the goal is to bring this technology and products into the market as new and effective products to treat patients at risk of acquiring dangerous skin and wound infections. 

Amferia’s approach to killing bacteria

  • 1. Binds and kills bacterial loads in seconds—including antibiotic resistant bacteria
  • 2. Highly potent and targets only bacteria
  • 3. Completely harmless to human and animal cells
  • 4. Does not release any antimicrobials into the wound environment

Using antimicrobial peptides in new ways mimicking the immune system

The science:

Antimicrobial peptides are powerful molecules based on the mammalian innate immune system that can rapidly and selectively kill bacteria including antibiotic resistant bacteria and prevent bacterial infections.

Until today, antimicrobial peptides have had poor stability

These peptides have been present in all mammals for millions of years and have an un-specific way of killing bacteria - by rapidly disrupting the bacteria’s cell membrane through something called electrostatic and amphiphilic interaction. In a way, this can be considered as a highly specialised soap-like molecule designed to kill bacteria by ripping off its skin. 

Antimicrobial peptides carry a net-positive charge, as well as a molecular structure that include hydrophobic and hydrophilic characteristics. These two factors allow peptides to attract bacterial cells—which carry a net-negative charge and are also amphiphilic—and bind to them, before puncturing their membrane and killing the cell. The opposite charge and amphiphilic structure attracts bacteria to the peptides and enables rapid disruption.

Because peptides destroy bacteria cells in a physical process, bacteria have very low probability of evolving resistance to peptides that they have been able to develop against antibiotics, which work chemically. 

Until today, antimicrobial peptides have had poor stability. In the past, antimicrobial peptides have been poor choices for clinical applications because of their fragility. High doses of antimicrobial peptides were needed for clinical applications, which increased costs and, since at those doses peptides were seen as pharma products, prolonged the time-to-market.

As a result, developing market-ready products featuring this valuable antimicrobial technology has faced insurmountable hurdles.

Amferia solves this problem by implementing a scientifically robust approach that covalently (or permanently) bind antimicrobial peptides to the surface of a soft, ordered and amphiphilic hydrogel pad.

These permanent bonds protect the vulnerable portion of the peptide molecule and fix them in place, while leaving their bacteria-killing mechanism free to attract and destroy bacterial cells.  Antimicrobial peptides fixed to an underlying hydrogel pad allowed Amferia to develop an efficient and cost-effective design for an antimicrobial wound dressing.  

Amferia solves this problem by permanently binding the peptides to an amphiphilic hydrogel

This design provides the needed balance between stability and activity.

The end-product is a singular material that does not leach or release any peptides or substances into the body, but rather acts locally as a contact-killing medical device—which will enable faster clinical translation.

Current antimicrobial peptide technologies utilize the peptide in its pristine form that renders them inactive in a few minutes. Amferia’s innovation enables the bound peptides to be stable and active for up to five days. The product we’re developing for wound care will be shelf-stable for up to a currently tested period of eighteen months, and potentially up to two years.

Read about our first product using the technology >

Years of research yield a breakthrough innovation

Technology:

Amferia’s technology is born out of years of research performed at Chalmers University of Technology. The concept behind Amferia’s antibacterial properties are enabled by a new material known as amphiphilic antimicrobial hydrogel.

An amphiphilic substance is one that displays both hydrophilic and hydrophobic characteristics. Comprised of more than 70% water, the hydrogel is soft and flexible, making it useful for numerous medical applications.

Amferia’s technology is based on a new material known as amphiphilic antimicrobial hydrogels

The surface of amphiphilic hydrogel consists of antimicrobial peptides that are permanently (or covalently) bound to the hydrogels amphiphilic structure - forming a single material. The material interact with the bacteria and when in contact, disrupts the bacterial cell wall rapidly, effectively killing the bacteria.

The amphiphilic antimicrobial hydrogel has proven to not release any substances into the environment. This singular material can be configured into antimicrobial products ranging from wound care dressings to antiseptic sprays to mechanically durable devices such as catheters and implants.  

To date, analysis confirms that Amferia amphiphilic antimicrobial hydrogel has upto 99.99% kill rate against multiple gram-negative and gram-positive bacterial strains, including MRSA, MDR E. Coli and Pseudomonas aeruginosa.

It has also been proven to be non-toxic to the body as per ISO 10993 biocompatibility evaluations, namely acute toxicity, cytotoxicity, skin sensitisation & irritation, implantation and material mediated pyrogenicity. 

Amferia's first product for human wound care and animal wound care has been developed with easy applicability and functionality, as proven in numerous pre-clinical and clinical studies. More products and broader applications are in the pipeline.

Read about possible applications of Amferia's innovation >

Amferia’s technology verified in scientific papers

Scientific evidence:

Amferia’s technology platform has been verified in numerous pre-clinical studies for both its antimicrobial efficacy and its safety in lab and animal studies. These studies have been published in peer-reviewed scientific journals.

The studies describe evidence of Amferia’s technology through fluorescence microscopy against multiple strains of bacteria, including resistant bacteria. An animal infection study demonstrates the realtime effectiveness of Amferia hydrogel in eradicating bacteria from a wound. 

In 2022, Amferia’s technology platform was verified in a new form for potential spray based applications. The base technology was reformulated as a small particles that can be sprayed for applications in deep wounds. The results demonstrated excellent reduction of the broad bacterial bio burden including resistant bacteria upto 4 log reduction (or 99.99%) bacterial colonies. This study and others are now published in peer-reviewed scientific journals as listed below. 

Pre-clinical studies in peer-reviewed scientific journals

First human study

Clinical studies:

Amferia dressing was applied on intact skin of lower arm of 40 healthy volunteers. The study was a randomised, double blinded, placebo controlled study for evaluating the efficacy of Amferia dressing on eradicating bacteria from a clinically relevant surface.

The human skin is a source of bacteria for certain wound infections, for example in surgery wounds. The reduction of bacteria on skin after 3 hours of dressing application was studied. An average bacterial reduction by 1000 times (i.e. 99.9%) and in some cases where bacterial load was high, almost 99.99% reduction was seen (as below), after application of Amferia wound dressing. 

The image below shows swab cultures from one sample and demonstrates the the antimicrobial efficacy of Amferia Hydrogel Wound Dressing, on human skin. The study and statistical analysis is now completed and under preparation to be published in a scientific journal.

Agneta Edberg appointed chairperson

July 28, 2022

Agneta has a solid background from the global Life science and Medtech field spanning over 30 years in leading roles such as; Sales &Marketing Director of Pharmacia (Pfizer), Senior VP and CEO of Mylan NordicPharmaceuticals, CEO of NM Pharma and more recently as the COO of Bactigaurd that manufactures a variety of antimicrobial device. Today, she works on theBoard of cutting-edge life-science SME’s guiding the companies for future success. Agneta’s extensive knowledge in the life science industry will be important for Amferia’s scale-up journey in both human and animal wound care.

Anand Kumar Rajasekharan, CEO of Amferia − “It is an honour to work with Agenta, whose impressive knowledge of the field and guidance greatly strengthens Amferia’s position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the first product launch for animal health, FDA and CE regulatory processes for human health and establishing a successful sales and marketing foundation for Amferia.”

Agneta Edberg − “Amferia is a company every board person wishes to work for. The technology offers a paradigm shift in wound care with nontoxic properties still killing bacteria, even the resistant ones. In a world where antimicrobial resistance is an increasing challenge to humanity, I am grateful to be a part of reducing that threat”

Amferia at the European Wound Management Association (EWMA) congress 2022 in Paris

May 17, 2022

EWMA is an important congress that brings together clinicians and healthcare  industry for important discussions within wound care for humans and animals. Amferia is eager to present our science, antimicrobial technology and introduce our first wound dressings for animal and human wound  care. We welcome all attendees to our stand located in

room 252A at the  congress venue, Palais  des Congrès de Paris, to know more about Amferia and  clinical evidence for human and animal wound care as well as for an  introduction to our soon-to-be launched wound dressings for animal wound  care. We also invite all  attendees to our scientific talk at the symposium for Veterinary Wound  Healing Association (VWHA) on 24th May at 08:45 hrs room 252A.

Amferia granted US patent for its antimicrobial material platform

May 9, 2022

Amferia AB announced today that it has been granted the foundational patent by the United States Patent and Trademark Office (USPTO)for its innovative antimicrobial material based on an amphiphilic antimicrobial hydrogel. The company is now in its final stages of product development for wound care applications and aims to launch the first product within animal health during 2022.

Top 100 research based innovations of 2021

May 26, 2021

Amferia’s technology recognized as one of the top 100 research based innovations of 2021 by the Royal Swedish Academy of Engineering Sciences.

Amferia & Triolab announce partnership to launch innovative wound care products for animal health

May 6, 2021

The joint partnership with Triolab will enable Amferia to reach the large Swedish veterinary market where wound care and infection prevention is of prime importance, which has been intensified with the growing threat of antibiotic resistant infections. Amferia and Triolab’s partnership will build on extensive data and feedback from Amferia’s ongoing product trials across Europe. The joint efforts will aim to market the products to selective veterinary clinics across Sweden during 2021 and further expansion in 2022.

Amferia raises SEK 6.2 million in pre-seed investment

January 22, 2020

Almi Invest, Chalmers Ventures, along with the British investor Corithinan Properties Ltd. and Let’s Deal Founder Alexander Hars have invested a total of SEK 6.2 million in the Gothenburg-based med-tech company Amferia, who has developed a wound care product with a patented material that actively combats infections and kills antibiotic-resistant bacteria.

“Every year, 700,000 people die globally as a result of infections caused by antibiotic-resistant bacteria and almost half of the infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives”, says Louise Warme, Investment Manager at Almi Invest.

Amferia establishes R&D operations at AstraZeneca’s BioVentureHub

October 28, 2019

Amferia is very excited to move into the BioVentureHub, given the strong benefits of operating in a flourishing environment with state-of-the-art infrastructure dedicated to medtech and life science companies. We are also eager to be around so many experts within life science ranging from established to early-stage companies researching in biopharmaceuticals, medical devices and diagnostics. Amferia looks forward to be part of, learn and grow in this supportive and exciting community.

At the Annual Veterinary Hygiene Conference 2019

October 24, 2019

We had the pleasure to attend the annual Veterinary Hygiene Conference in Knivsta, Stockholm. One of the primary questions of this conference was about handling antibiotic resistant infections in animal wound care – a fast growing problem in Sweden and Globally. Many interesting & enlightening discussions with expert veterinary clinicians taught us a lot about the needs and challenges in animal wound care and how Amferia might expand its innovative solutions to help veterinary healthcare. Thanks for a great conference VVHF.

Amferia wins the Start-up of the Year award at Venture Cup Sweden 2019

September 20, 2019

The Jury's motivation for choosing Amferia as the winners! “With its disruptive solution, the team has the opportunity to shake several industries as they tackle one of humanity’s greatest global threats. By addressing a world problem, millions of lives will be saved. By changing the behavior of the consumer, there is also the potential to reform the market.”

Amferia receives the prestigious EU SME Instrument (Phase 1) grant from the European Union

August 1, 2019

Amferia receives the highly competitive and coveted EU SME Instrument Phase 1 grant of 50 000 Euros along with the valuable business network to take forward our technology into the market.